Key Points
- Wendy Becker purchased 411 GSK shares on March 20 at GBX 1,963 (~£8,068) and had previously bought 3,334 shares on February 20 at GBX 2,219, signaling continued insider accumulation.
- Other senior insiders also bought stock this week and GSK repurchased 560,000 ordinary shares under an expanded share buyback, actions that reduce float and signal management confidence.
- GSK has a market cap of £77.78bn and a P/E of 13.97 with an average analyst rating of Hold (average target GBX 1,917.86), while its lung cancer treatment secured orphan drug designation in Japan — a potential regulatory positive.
GSK plc (LON:GSK - Get Free Report) insider Wendy Becker acquired 411 shares of the business's stock in a transaction on Friday, March 20th. The shares were bought at an average price of GBX 1,963 per share, with a total value of £8,067.93.
Wendy Becker also recently made the following trade(s):
- On Friday, February 20th, Wendy Becker acquired 3,334 shares of GSK stock. The shares were purchased at an average price of GBX 2,219 per share, with a total value of £73,981.46.
GSK Price Performance
GSK stock opened at GBX 1,939 on Tuesday. The company has a market capitalization of £77.78 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 1.24 and a beta of 0.32. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 108.20. GSK plc has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 2,282. The stock's 50 day moving average is GBX 2,026.08 and its 200-day moving average is GBX 1,820.75.
GSK (LON:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. Equities research analysts expect that GSK plc will post 175.980975 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the stock. Shore Capital Group reaffirmed a "buy" rating and set a GBX 2,300 price target on shares of GSK in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft raised their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a "hold" rating in a report on Thursday, January 15th. Citigroup boosted their price target on GSK from GBX 1,900 to GBX 2,250 and gave the company a "buy" rating in a research note on Monday, February 9th. UBS Group reiterated a "neutral" rating and issued a GBX 1,940 price target on shares of GSK in a research note on Friday, January 23rd. Finally, Berenberg Bank raised their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a "hold" rating in a research note on Monday, November 24th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of GBX 1,917.86.
Read Our Latest Analysis on GSK
Key GSK News
Here are the key news stories impacting GSK this week:
- Positive Sentiment: Senior insiders bought stock this week, signaling confidence from management: Jonathan Symonds purchased 5,000 shares at GBX 1,951 (~£97,550), Wendy Becker bought 411 shares at GBX 1,963 (~£8,068) and Anne Beal bought 196 shares (reported at GBX 5,179) — insider buying often suggests executives view the shares as undervalued.
- Positive Sentiment: GSK expanded its buyback program and increased treasury holdings, repurchasing 560,000 ordinary shares on 20 March (via BNP), which reduces float and supports EPS. Article Title
- Positive Sentiment: Regulatory progress: GSK’s lung cancer treatment received orphan drug designation in Japan, which can enable regulatory incentives, market exclusivity and a faster development path in that market. Article Title
- Neutral Sentiment: GSK admitted 96,525 new ordinary shares to trading under employee share plans — standard issuance for employee compensation; modest dilution but typical and usually neutral for near-term valuation. Article Title
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
